1887

Abstract

Residual viraemia is detectable in the majority of human immunodeficiency virus (HIV)-infected subjects with plasma HIV-1 RNA <50 copies ml. In the present study, the impact of repeated treatment interruptions on residual HIV-1 viraemia was investigated in 58 subjects enrolled in the ISS-PART, a multicentre, randomized clinical trial comparing 24 months of continuous (arm A) and intermittent (arm B) highly active antiretroviral therapy (HAART). Residual viraemia was measured by a modified Roche Amplicor HIV-1 RNA assay (limit of detection 2.5 copies ml). At baseline, the median value of residual viraemia was 2.5 copies ml in both arms; after 24 months, the median value was 2.5 in arm A and 8.3 in arm B. The median change from baseline to month 24 was significantly different between patients under continuous or intermittent HAART: 0 copies ml (range −125.2 to +82.7) of HIV-1 RNA in arm A versus 2.1 copies ml (range −80 to +46.8) in arm B (=0.024). These results suggest that intermittent HAART tends to modify HIV-1 viraemia set point even if a virological response is achieved after HAART reinstitution.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.004630-0
2009-01-01
2019-10-15
Loading full text...

Full text loading...

/deliver/fulltext/jmm/58/1/121.html?itemId=/content/journal/jmm/10.1099/jmm.0.004630-0&mimeType=html&fmt=ahah

References

  1. Ananworanich, J. & Hirschel, B. ( 2007; ). Intermittent therapy for the treatment of chronic HIV infection. AIDS 21, 123–124.[CrossRef]
    [Google Scholar]
  2. Dornadula, G., Zhang, H., VanUitert, B., Stern, J., Livornese, L., Jr, Ingerman, L. J., Witek, J., Kedanis, R. J., Natkin, J. & other authors ( 1999; ). Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282, 1627–1632.[CrossRef]
    [Google Scholar]
  3. Finzi, D., Blanckson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Liszewicz, J., Lori, F. & other authors ( 1999; ). Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5, 512–517.[CrossRef]
    [Google Scholar]
  4. Frost, S. D. W., Martinez-Picado, J., Ruiz, L., Clotet, B. & Brown, A. J. ( 2002; ). Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection. J Virol 76, 968–979.[CrossRef]
    [Google Scholar]
  5. Havlir, D. V., Strain, M. C., Clerici, M., Ignacio, C., Trabattoni, D., Ferrante, P. & Wong, J. K. ( 2003; ). Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type-1 infected persons treated with suppressive antiretroviral therapy for five years. J Virol 77, 11212–11219.[CrossRef]
    [Google Scholar]
  6. Havlir, D. V., Koelsch, K. K., Strain, M. C., Margot, N., Biao, L., Ignacio, C. C., Miller, M. D. & Wong, J. K. ( 2005; ). Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis 191, 1164–1168.[CrossRef]
    [Google Scholar]
  7. Maldarelli, F., Palmer, S., King, M. S., Wiegand, A., Polis, M. A., Mican, J., Kovacs, J. A., Davey, R. T., Rock-Kress, D. & other authors ( 2007; ). ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 3, e46 [CrossRef]
    [Google Scholar]
  8. McKinnon, J. E., Arribas, J. R., Pulido, F., Delgado, R. & Mellors, J. W. ( 2006; ). The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone. AIDS 20, 2331–2335.[CrossRef]
    [Google Scholar]
  9. Palmer, S., Maldarelli, F., Wiegand, A., Bernstein, B., Hanna, G. J., Brun, S. C., Kempf, D. J., Mellors, J. W., Coffin, J. M. & King, M. S. ( 2008; ). Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. . Proc Natl Acad Sci U S A 105, 3879–3884.[CrossRef]
    [Google Scholar]
  10. Palmisano, L., Giuliano, M., Nicastri, E., Pirillo, M. F., Andreotti, M., Galluzzo, C. M., Bucciardini, R., Fragola, V., Andreoni, M. & Vella, S. ( 2005; ). Residual viremia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy. AIDS 19, 1843–1847.[CrossRef]
    [Google Scholar]
  11. Palmisano, L., Giuliano, M., Bucciardini, R., Fragola, V., Andreotti, M., Galluzzo, C. M., Pirillo, M. F., Weimer, L. E., Arcieri, R. & other authors ( 2007; ). Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study. J Acquir Immune Defic Syndr 46, 39–47.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.004630-0
Loading
/content/journal/jmm/10.1099/jmm.0.004630-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error